= CERTAIN INFORMATION HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS OF THE TYPE THAT THE REPORTING PERSON CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL ARCUS BIOSCIENCES, INC. THIRD AMENDED AND RESTATED COMMON STOCK PURCHASE...Common Stock Purchase Agreement • January 31st, 2024 • Gilead Sciences, Inc. • Biological products, (no disgnostic substances) • New York
This Third Amended and Restated Common Stock Purchase Agreement (this “Agreement”) is dated as of January 29, 2024, by and between Arcus Biosciences, Inc., a Delaware corporation (the “Company”), and Gilead Sciences, Inc., a Delaware corporation (“Gilead”). This Agreement amends and restates in its entirety the Second Amended and Restated Common Stock Purchase Agreement entered into between the Company and Gilead on June 27, 2023 (the “Existing Purchase Agreement”), which amended the Common Stock Purchase Agreement, dated May 27, 2020, by and between the Company and Gilead (the “Original Agreement”), as previously amended and restated on January 31, 2021.
= CERTAIN INFORMATION HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED ARCUS BIOSCIENCES, INC. AMENDED & RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • January 31st, 2024 • Gilead Sciences, Inc. • Biological products, (no disgnostic substances) • New York
This Amended and Restated Investor Rights Agreement (this “Agreement”) is made as of January 29, 2024 (the “Effective Date”), by and between Arcus Biosciences, Inc., a Delaware corporation (the “Company”) and Gilead Sciences, Inc., a Delaware corporation (“Gilead”). This Agreement amends and restates in its entirety the Investor Rights Agreement entered into between the Company and Gilead on May 27, 2020 (the “Original Agreement”), as previously amended on October 11, 2022.
